Economic Evaluation of Penpulimab Plus Paclitaxel and Carboplatin Combination Therapy as First-Line Treatment for Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer in China
Our analysis suggests that penpulimab plus paclitaxel and carboplatin combination therapy is cost-effective for patients with locally advanced or metastatic sqNSCLC in China.
Authors
- Eui‐Kyung Lee (ORCID: https://orcid.org/0000-0003-0601-7754)
- Yongfa Chen (ORCID: https://orcid.org/0000-0001-5980-5231)
- Meng Han (ORCID: https://orcid.org/0000-0002-2492-0907)
- Hye-In Jung
Institutions
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Clinical Drug Investigation
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1007/s40261-025-01439-6
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Sungkyunkwan University
- China Scholarship Council